CRBP analyst estimates
Corbus (CRBP) analyst ratings, the average price target and its range, and every firm's latest call.
CRBP analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 26, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP) | $35.00 |
| Aug 13, 2026 | Mizuho Securities | Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Mizuho | $33.00 |
| May 22, 2026 | Mizuho Securities | Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho | $44.00 |
| May 12, 2026 | Jefferies | Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies | $33.00 |
| Oct 29, 2025 | Mizuho Securities | Corbus Pharmaceuticals price target raised to $39 from $32 at Mizuho | $39.00 |
| Oct 20, 2025 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP) | $40.00 |
| Oct 20, 2025 | Piper Sandler | Corbus Pharmaceuticals price target raised to $51 from $35 at Piper Sandler | $51.00 |
| Dec 2, 2024 | Piper Sandler | Piper Sandler Starts Corbus Pharmaceuticals (CRBP) at Overweight | $35.00 |
| Oct 21, 2024 | Oppenheimer | Oppenheimer Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) | $60.00 |
| Sep 20, 2024 | B.Riley Financial | Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at B.Riley | $40.00 |
| Sep 13, 2024 | Mizuho Securities | Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) | $74.00 |
| Aug 7, 2024 | Oppenheimer | Corbus Pharmaceuticals (CRBP) PT Raised to $88 at Oppenheimer | $88.00 |
| Jul 22, 2024 | H.C. Wainwright | Corbus Pharmaceuticals resumed with a Buy at H.C. Wainwright | $80.00 |
| Jun 11, 2024 | RBC Capital | Corbus Pharmaceuticals (CRBP) PT Raised to $82 at RBC Capital | $82.00 |
| Jun 3, 2024 | Oppenheimer | Corbus Pharmaceuticals (CRBP) PT Raised to $80 at Oppenheimer | $80.00 |
- 7 firms rate CRBP: 7 buy, 0 hold, 0 sell.
- The average price target is $33.67 from 3 analysts, from $33.00 to $35.00.
Updated 2026-11-03 23:14 UTC